, radiotherapy, and targeted therapy. The chemotherapeutic drugs used were vinorelbine, gemcitabine, UFUR (tegafur/uracil), CMF (cyclophosphamide, methotrexate, and fluorouracil), eribulin, capecitabine, and paclitaxel, and the endocrine drugs were goserelin
Search Results
Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification
Fiona Tsui-Fen Cheng, Fu Ou-Yang, Nina Lapke, Kai-Che Tung, Yen-Kung Chen, Yuh-Yu Chou, and Shu-Jen Chen
Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations
Gayathri Nagaraj and Cynthia X. Ma
, luminal B, HER2-enriched, and basal-like, 15 which are associated with a different clinical course and sensitivity to chemotherapy. 16 Basal-like and HER2-enriched subgroups are associated with the highest rates of pCR to paclitaxel- and doxorubicin
A Change of Heart
Crystal S. Denlinger
guidelines, visit NCCN.org 4. Romond EH Jeong JH Rastogi P . Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab
New Treatment Guidelines for Penile Cancer
Philippe E. Spiess
distant disease) were treated with neoadjuvant chemotherapy (paclitaxel, ifosfamide, and cisplatin) and then surgical resection. They reported an objective response rate of 50%. “On the whole, this is far superior to what we see traditionally with surgery
Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–2013
Talia Golan, Tal Sella, Ofer Margalit, Uri Amit, Naama Halpern, Dan Aderka, Einat Shacham-Shmueli, Damien Urban, and Yaacov Richard Lawrence
a significant benefit in OS over gemcitabine monotherapy, until recently. In 2011 and 2013, progress was made with the publication of the PRODIGE 4/ACCORD 11 4 and MPACT 5 studies, showing survival benefits for FOLFIRINOX and gemcitabine/nab-paclitaxel
Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report
Quanying Tang, Tong Li, Fan Ren, Xuanguang Li, WeiBo Cao, Haochuan Yu, Fuling Mao, Cancan Cao, Lingling Zu, and Song Xu
have suggested that KANK1 , a tumor suppressor gene, can mediate paclitaxel resistance in lung adenocarcinoma A549 cells. In addition, a previous study also reported a pancreatic neuroendocrine carcinoma patient with a KANK1::ALK fusion who exhibited
Updates in the Treatment of Metastatic Urothelial Cancer
Presented by: Thomas W. Flaig
, paclitaxel, or vinflunine). 2 Key findings from the study included an improved overall response rate (ORR) with enfortumab vedotin (40.6%) compared with standard chemotherapy (17.9%). Complete response rates were also increased with enfortumab vedotin (4
Advances in the Management of Metastatic Breast Cancer
Presented by: William J. Gradishar
chemotherapy as a first-line treatment of PD-L1–positive TNBC. The study compared pertuzumab and chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin) with chemotherapy alone in patients who had not received prior treatment of metastatic disease
Updates in the Management of Hepatobiliary Cancers
Presented by: Mitesh J. Borad
doublet regimen with a significant improvement in OS, paved the way for SWOG 1815, which compared gemcitabine, cisplatin, and nab-paclitaxel with gemcitabine + cisplatin. Although there was a numerical improvement in PFS, OS, and response rates among the
Esophageal and Esophagogastric Junction Cancers
Jaffer A. Ajani, James S. Barthel, David J. Bentrem, Thomas A. D'Amico, Prajnan Das, Crystal S. Denlinger, Charles S. Fuchs, Hans Gerdes, Robert E. Glasgow, James A. Hayman, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, A. Craig Lockhart, Mary F. Mulcahy, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Thomas K. Varghese Jr., Graham Warren, Mary Kay Washington, Christopher Willett, and Cameron D. Wright
chemoradiation with carboplatin and paclitaxel was also well-tolerated, resulting in superior overall and disease-specific survivals compared with cisplatin and irinotecan in patients with locally advanced esophageal cancer. 136 In a retrospective study